2 6 Anti-VEGF therapy reduces the risk of PDR or CI-DME development by ~50% Zenkuda in Diabetic Retinopathy: A large, undertreated disease with meaningful risk progression *The CDC defines VTDR as severe NPDR, PDR, and/or DME 1. Roche epidemiology data from 2025. 2. CDC accessed May 13: https://www.cdc.gov/vision-health-data/prevalence-estimates/dr-prevalence.html. 3. Moshfeghi AA, et al. BMC Ophthalmol. 2024 May 31;24(1):229. 4 Maturi RK et al; DRCR Retina Network. JAMA Ophthalmol. 2021 Jul 1;139(7):701-712. ~81% ~19%* Vision- threatening disease Non-vision threatening DR • Damage occurring in eye • Symptoms may not be present • Damage occurring in eye • Usually no symptoms • Damage occurring in eye • Symptoms usually present • Vision threatening Stages of DR People in the U.S. have DR 1,2 ~9.6M DR can progress quickly into vision- threatening PDR or DME 3 • DME can occur at any stage, but the risk increases as DR worsens • 50% of moderate NPDR and 60% of severe NPDR eyes developed vision- threatening DME by Year 4 Anti-VEGF therapy reduces the risk of PDR or DME development by ~50% 3,4 • Compared to laser or no treatment • Repeated anti-VEGF injections are required to maintain the benefits of therapy DME can occur at any stage